BKT-140
CAS No. 664334-36-5
BKT-140( BL-8040 | TF-14016 | 4F-Benzoyl-TN14003 )
Catalog No. M15531 CAS No. 664334-36-5
BKT-140 (TF-14016) is a 14-residue bio stable synthetic peptide; high-affinity CXCR4 antagonist(IC50=1 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 672 | Get Quote |
|
| 50MG | 1071 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBKT-140
-
NoteResearch use only, not for human use.
-
Brief DescriptionBKT-140 (TF-14016) is a 14-residue bio stable synthetic peptide; high-affinity CXCR4 antagonist(IC50=1 nM).
-
DescriptionBKT-140 (TF-14016) is a 14-residue bio stable synthetic peptide; high-affinity CXCR4 antagonist(IC50=1 nM); inhibits CXCL12-mediated migration of human Jurkat cells and mouse splenocyte in a dose-dependent manner in vitro (IC50=0.65 and 0.54 nM, respectively); ameliorates severity in collagen-induced arthritis in mice.Blood Cancer Phase 2 Clinical.
-
In VitroMotixafortide (BKT140) displays selective toxicity toward AmL and MM cells. Treatment with Motixafortide (BKT140) can overcome IL-6 dependent proliferation and survival of ARH77 MM cells. Motixafortide (BKT140) specifically triggers CXCR4-dependent cell death in leukemia and MM cells. Motixafortide (BKT140) stimulates apoptotic cell death in leukemia and MM cells.
-
In VivoSubcutaneous injections of Motixafortide (BKT140) significantly reduces, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts. Tumors from animals treated with Motixafortide (BKT140) are smaller in size and weights, had larger necrotic areas and high apoptotic scores.
-
SynonymsBL-8040 | TF-14016 | 4F-Benzoyl-TN14003
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number664334-36-5
-
Formula Weight2159.52
-
Molecular FormulaC97H144FN33O19S2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 36 mg/mL
-
SMILESC1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
-
Chemical NameL-Argininamide, N2-(4-fluorobenzoyl)-L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4→13)-disulfide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tamamura H, et al. FEBS Lett. 2004 Jul 2;569(1-3):99-104.
2. Peled A, et al. Clin Cancer Res. 2014 Jan 15;20(2):469-79.
3. Beider K, et al. Exp Hematol. 2011 Mar;39(3):282-92.
molnova catalog
related products
-
E 6130
A potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM.
-
SCH-546738
SCH-546738 (SCH546738) is a potent, selective and non-competitive CXCR3 antagonist with binding Ki of 0.4 nM for human CXCR3.
-
RAMX3
A tritium-labeled allosteric modulator of the human chemokine receptor CXCR3 with Kd of 1.08 nM.
Cart
sales@molnova.com